中国实用外科杂志2025，Vol.45Issue(6)：645-649,5.DOI:10.19538/j.cjps.issn1005-2208.2025.06.08
胰腺癌术后辅助治疗研究进展
Adjuvant therapy after surgery in pancreatic cancer:Research progress
摘要
Abstract
Postoperative adjuvant therapy for pancreatic cancer has become the core component of comprehensive management.The mainstream regimens include gemcitabine monotherapy,gemcitabine combined with capecitabine,modified FOLFIRINOX,and gemcitabine combined with S-1.Full-dose and full-cycle chemotherapy is crucial to improving survival benefits for patients.Biomarkers such as circulating tumor cells(CTCs)and circulating tumor DNA(ctDNA),as well as technologies such as patient-derived organoid(PDO)drug sensitivity testing and artificial intelligence-assisted transcriptomic analysis,provide important support for precise and individualized adjuvant therapy.Adjuvant radiotherapy,targeted therapy,and immunotherapy show potential in high-risk patients.Future research should focus on head-to-head comparisons of multiple regimens and molecular stratification guidance to optimize combination therapy strategies and continuously enhance survival benefits for patients.关键词
胰腺癌/辅助治疗/化疗/靶向治疗Key words
pancreatic cancer/postoperative adjuvant therapy/chemotherapy/targeted therapy分类
医药卫生引用本文复制引用
刘悦泽,张锰钢,张太平..胰腺癌术后辅助治疗研究进展[J].中国实用外科杂志,2025,45(6):645-649,5.基金项目
National Natural Science Foundation of China(No.82272917,No.82172836) （No.82272917,No.82172836）
Fundamental Research Funds for the Central Universities(No.3332024117) 国家自然科学基金项目(No.82272917,No.82172836) （No.3332024117）
中央高校基本业务科研费项目(No.3332024117) （No.3332024117）
